Counting Replication Origins to Measure Growth of Pathogens by Charbon, Godefroid et al.
u n i ve r s i t y  o f  co pe n h ag e n  
Counting Replication Origins to Measure Growth of Pathogens
Charbon, Godefroid; Haugan, Maria Schei; Frimodt-Møller, Niels; Løbner-Olesen, Anders
Published in:
Antibiotics
DOI:
10.3390/antibiotics9050239
Publication date:
2020
Document version
Publisher's PDF, also known as Version of record
Document license:
CC BY
Citation for published version (APA):
Charbon, G., Haugan, M. S., Frimodt-Møller, N., & Løbner-Olesen, A. (2020). Counting Replication Origins to
Measure Growth of Pathogens. Antibiotics, 9(5), [239]. https://doi.org/10.3390/antibiotics9050239
Download date: 23. jun.. 2020
antibiotics
Commentary
Counting Replication Origins to Measure Growth
of Pathogens
Godefroid Charbon 1 , Maria Schei Haugan 2, Niels Frimodt-Møller 3 and
Anders Løbner-Olesen 1,*
1 Department of Biology, University of Copenhagen, Ole Maaløes vej 5, 2200 Copenhagen N, Denmark;
godefroid.charbon@bio.ku.dk
2 Department of Medical Microbiology, St. Olavs Hospital, Trondheim University Hospital, 7006 Trondheim,
Norway; maria.schei.haugan@stolav.no
3 Department of Clinical Microbiology, Rigshospitalet, 2100 Copenhagen, Denmark;
niels.frimodt-moeller@regionh.dk
* Correspondence: lobner@bio.ku.dk; Tel.: +45-3532-2068
Received: 2 April 2020; Accepted: 5 May 2020; Published: 8 May 2020


Abstract: For the past several decades, the success of bacterial strains in infecting their host has been
essentially ascribed to the presence of canonical virulence genes. While it is unclear how much growth
rate impacts the outcome of an infection, it is long known that the efficacy of the most commonly
used antibiotics is correlated to growth. This applies especially to β-lactams, whose efficacy is nearly
abolished when cells grow very slowly. It is therefore reasonable to assume that a niche or genetic
dependent change in growth rate could contribute to the variability in the outcome of antibiotic
therapy. However, little is known about the growth rate of pathogens or their pathotypes in their host.
Keywords: growth rate; pathogen; in situ; antibiotics; DNA
1. Introduction
Recently, efforts have been made to understand the growth dynamics of bacteria in situ. Classically,
bacterial population dynamics are observed by viable cell counting using colony forming units (CFUs).
This gives a good indication of the size of the bacterial population at the time of sampling. Although,
because a change in bacterial load results from both cell growth and cell death, it fails to measure how
fast bacteria are growing (Figure 1).
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Figure 1. In situ population dynamics. The size of a bacterial population is determined by how fast 
individual cells grow and how fast the cells are killed by antibiotics or immune system defense 
mechanisms. 
Simply put, the same CFU count can be obtained from a population of cells growing fast with a 
high death rate, as from a population of cells growing slowly with a low death rate. In test tube 
Figure 1. In situ population dynamics. The size of a bacterial population is determined by
how fast individual cells grow and how fast the cells are killed by antibiotics or immune system
defense mechanisms.
Simply put, the same CFU count can be obtained from a population of cells growing fast with
a high death rate, s from a populatio of cells growing slowly with a low death rate. In test tube
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experiments, growth is usually measured by change in optical density. This is obviously not feasible
in in-host setups, and death rate attributed to immune system response or antibiotics is not taken
into account.
2. DNA Replication as a Growth Marker
Lately, several methods have been applied to infer the in situ growth rate of bacteria [1–8]. One of
these methods takes advantage of the coupling of DNA replication with growth rate. In Escherichia
coli and other bacteria, initiation of DNA replication is linked to growth rate changed by nutrient
availability [9,10]. In E. coli, it takes a minimum of ~60 min to finish a cell cycle. The bidirectional DNA
duplication starts from the origin of replication (oriC) and finishes at the terminus (ter), a minimum
of 40 min later (C period). Subsequently, it takes ~20 min for the cell to divide (D period). Thus,
the oriC copy number is increased for a certain amount of time before the ter copy number increases.
In cells growing very slowly, DNA is replicated in a small proportion of the cell cycle, while during
fast growth, cells are born with overlapping rounds of DNA replication. The upshot is that the ratio of
oriC to ter reflects the growth rate of a bacterium. Invariably, in a population of actively replicating
cells, oriC/ter is above 1 (Figure 2).
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Figure 2. Origin of replication/terminus (oriC/ter) ratio as a measure of growth rate. Non-growing 
cells (left) possess fully replicated chromosomes with one oriC (blue ball) and one ter (orange ball). 
During the DNA duplication period of growing cells (right), there are more oriC than ter. Thus, the 
oriC/ter ratio of the population is above 1. 
Already, this information becomes valuable to distinguish growing cells from non-growing 
cells; non-growing cells do not replicate their DNA, thus oriC/ter is equal to one. Cells growing faster 
than it takes to finish a cell cycle (C+D) are born with chromosomes in the process of being 
replicated, thus multiple oriC per one ter. For example, a population of E. coli growing in rich media 
or in situ can have eight oriC in a single cell and an oriC/ter ratio of about four. The faster the cells 
grow the more oriC per ter. This remarkable correlation has long been acknowledged, but only 
recently has it been used as a proxy to measure growth of pathogens in their host. This has been 
done by quantitative PCR amplification of oriC and ter [11–13], marker frequency analysis by whole 
genome sequencing [3,4,14–16], or direct microscopic visualization of fluorescently labeled oriC and 
ter in live cells [11,13], all of which will be referred to as marker frequency analysis (MFA) in the text. 
The value of the information obtained from such techniques is made apparent in some examples 
from recent studies that will be discussed below.  
3. Dynamics in Specific Niches  
The first example of this application comes from the study of uropathogenic E. coli (UPEC) 
causing urinary tract infections. Human urine was long thought to be too toxic to accommodate any 
kind of growth. Yet, growth of UPEC has been measured to be extremely fast (faster or similar to 
growth in Lysogeny broth rich medium) [4]. This shows that the bacterium not only thrives in the 
urinary tract, but also implies that fast growth could be mechanistically required for bacterial 
maintenance in niches with fast fluidic discharge. Using MFA for measuring growth, a similar 
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Already, this information becomes valuable to distinguish growing cells from non-growing cells;
non-growing cells do not replicate their DNA, thus oriC/ter is equal to one. Cells growing faster than
it takes to finish a cell cycle (C+D) are born with chromosomes in the process of being replicated,
thus multiple oriC per one ter. For example, a population of E. coli growing in rich media or in
situ can have eight oriC in a single cell and an oriC/ter ratio of about four. The faster the cells grow
the more oriC per ter. This remarkable correlation has long been acknowledged, but only recently
has it been used as a proxy to measure growth of pathogens in their host. This has been done by
quantitative PCR amplification of oriC and ter [11–13], marker frequency analysis by whole genome
sequencing [3,4,14–16], or direct microscopic visualization of fluorescently labeled oriC and ter in live
cells [11,13], all of which will be referred to as marker frequency analysis (MFA) in the text. The value
of the information obtained from such techniques is made apparent in some examples from recent
studies that will be discussed below.
3. Dynamics in Specific Niches
The first example of this application comes from the study of uropathogenic E. coli (UPEC) causing
urinary tract infections. Human urine was long thought to be too toxic to accommodate any kind of
growth. Yet, growth of UPEC has been measured to be extremely fast (faster or similar to growth in
Lysogeny broth rich medium) [4]. This shows that the bacterium not only thrives in the urinary tract,
but also implies that fast growth could be mechanistically required for bacterial maintenance in niches
Antibiotics 2020, 9, 239 3 of 5
with fast fluidic discharge. Using MFA for measuring growth, a similar mechanism was proposed for
Staphylococcus aureus growing in the nasal cavity [2]. There are also a significant number of bacteria
that cannot be grown in synthetic media, their existence only revealed by DNA sequencing. Here,
growth rate derived from MFA has been valuable to obtain very basic data on their growth in situ [14].
4. Dynamics During an Infection Process
In the second example, focus is placed on the population dynamics during infection: Are there
few bacteria at the infection site because they grow slowly or is it because they are cleared by the
immune system despite fast growth? (Figure 1). Common to the few studies made so far, is that there
is a not a clear correlation between the bacterial load (CFU per gram) and the growth rate measured at
the site of infection. This is exemplified in an analysis of the gut microbiome in an infant developing
necrotizing enterocolitis, revealing that the load of Clostridium species was very low despite rapid
bacterial growth [14]. In another example following the dynamics of a mouse peritoneal infection
over time, the load of E. coli at the primary site of infection increased and reached a plateau [11].
This apparent plateau in bacterial load is made up of both slowly growing and non-growing cells
kept in check by the host immune system. A low load of E. coli was also found in the bloodstream;
however, the growth rate of the bacteria in the blood mirrored the one found in the peritoneal cavity
throughout the infection. This supports the concept that the bacteria found in the bloodstream are not
establishing themselves but represent a mere spill-over from the site of infection. The conclusion from
this study was that the mouse immune system is presumably capable of better clearance of E. coli in
the bloodstream than in the peritoneum.
5. Dynamics During Antibiotic Therapy
Finally, knowledge about in situ bacterial growth could be used to select appropriate antibiotics or
predict their efficacy. For example, this is seen when analyzing the efficacy of antibiotics in eradicating an
E. coli infection from the mouse peritoneum [13]. Before antibiotic treatment, the bacterial population
was made up of non-growing and slowly growing cells. Treatment with ceftriaxone, a β-lactam
drug, preferentially eliminated growing cells, consistent with what is known about this class of
antibiotics [17,18] (Figure 3). This type of analysis is now expanded to analyze E. coli during human
urinary tract infection therapy [12].
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Figure 3. Measure of growth rate as read out for antibiotic efficacy. Selective action of β-lactams on
actively growing cells (more than one oriC per ter) is represented.
6. Concluding Remarks
While it is established that a variety of E. coli can cause human infection, it is now also clear
that the pathogens do not invariably grow at the same pace. The use of MFA to measure bacterial
growth dynamics during infection provides a potential for future patient-bacterium specific antibiotic
treatment regimens.
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